Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Medical Research Council's AML 10 Children Trial commenced in 1988. It is a multicentre collaborative study based on 4 courses of intensive chemotherapy with additional allogeneic bone marrow transplantation for children with a matched sibling donor. The remaining children are randomised either to an autologous transplant using unpurged marrow or stopping therapy. To date 156 eligible patients have been entered with a CR rate of 91%. 56% of children are still alive 2 years after trial entry and 57% are in CR 3 years after achieving CR. The treatment regimen is intensive but mortality and morbidity are acceptable. The study will need to accrue patients for a further 2 to 3 years in the hope of defining the role of allogeneic and autologous marrow transplantation.

Type

Conference paper

Publication Date

1992

Volume

6 Suppl 2

Pages

55 - 58

Keywords

Acute Disease, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Transplantation, Child, Child, Preschool, Combined Modality Therapy, Cytarabine, Daunorubicin, Etoposide, Humans, Infant, Leukemia, Myeloid, Recurrence, Remission Induction, Thioguanine, United Kingdom